Dr. Reddy’s Laboratories Ltd. announced the signing of a deal to divest certain non-core brands of the company in the dermatology segments to Eris Lifesciences Limited. Under the agreement, Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy’s for a consideration of Rs. 275 cr. As per IQVIA MAT December 2022,…
The Sistema Group company, Binnopharm Group, one of the leading pharmaceutical production companies in Russia via its affiliate Joint Stock Company ‘Alium’, and Dr. Reddy’s Laboratories Ltd., along with its subsidiaries together referred to as “Dr. Reddy’s”), an integrated global pharmaceutical company, announced the signing of a deal that will allow Binnopharm Group to acquire…
SVAAS Wellness Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and ICICI Lombard General Insurance Company Limited announced a partnership for the pilot launch of a first-of-its-kind cashless outpatient offering in India. The partnership marks the launch of Dr. Reddy’s digital health solution ‘SVAAS’ and demonstrates ICICI Lombard’s deeper foray into the wellness space.…
Dr. Reddy’s announced the launch of AVIGAN (Favipiravir) 200 mg Tablets in India. The launch is part of the global licensing agreement with FUJIFILM Toyama Chemical Co. Ltd. that grants Dr. Reddy’s the exclusive rights to manufacture, sell and distribute AVIGAN (Favipiravir) 200 mg Tablets in India. AVIGAN (Favipiravir) has been approved by the Drugs…